Accéder au contenu
Merck
  • Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.

Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.

Journal of medicinal chemistry (2008-06-19)
Paige E Mahaney, Lori K Gavrin, Eugene J Trybulski, Gary P Stack, T An Vu, Stephen T Cohn, Fei Ye, Justin K Belardi, Arthur A Santilli, Joseph P Sabatucci, Jennifer Leiter, Grace H Johnston, Jenifer A Bray, Kevin D Burroughs, Scott A Cosmi, Liza Leventhal, Elizabeth J Koury, Yingru Zhang, Cheryl A Mugford, Douglas M Ho, Sharon J Rosenzweig-Lipson, Brian Platt, Valerie A Smith, Darlene C Deecher
RÉSUMÉ

Further exploration of the cycloalkanol ethylamine scaffold, of which venlafaxine ( 1) is a member, was undertaken to develop novel and selective norepinephrine reuptake inhibitors (NRIs) for evaluation in a variety of predictive animal models. These efforts led to the discovery of a piperazine-containing analogue, 17g (WY-46824), that exhibited potent norepinephrine reuptake inhibition, excellent selectivity over the serotonin transporter, but no selectivity over the dopamine transporter. Synthesis and testing of a series of cyclohexanol ethylpiperazines identified ( S)-(-)- 17i (WAY-256805), a potent norepinephrine reuptake inhibitor (IC 50 = 82 nM, K i = 50 nM) that exhibited excellent selectivity over both the serotonin and dopamine transporters and was efficacious in animal models of depression, pain, and thermoregulatory dysfunction.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ethylamine solution, 66.0-72.0% in H2O
Sigma-Aldrich
Ethylamine solution, 2.0 M in THF
Sigma-Aldrich
Ethylamine solution, 2.0 M in methanol